HSIC · Henry Schein, Inc.

Henry Schein’s Q1 2026 results reflect continued execution against its strategic plan, with revenue growth accelerating to 6.3% YoY—outpacing prior-year comparisons and driven by broad-based strength across segments: Global Dental Distribution (+9.0%), Global Value-Added Services (+10.6%), and Global Specialty Products (+8.1%). Internal sales growth of 2.5% signals underlying demand resilience, while foreign currency contributed 3.1% of the top-line increase. Margin expansion is evident in the non-GAAP metrics: non-GAAP diluted EPS rose 14.8% YoY to $1.32, outpacing GAAP EPS growth of 4.5%, underscoring the impact of value-creation initiatives—including the $11M remeasurement gain from the S.I.N. distributor acquisition—and disciplined cost management. Management explicitly tied the $125M run-rate operating income improvement target by year-end 2026 to these initiatives, reinforcing confidence in delivering high-single-digit to low-double-digit earnings growth over time. The reaffirmation of full-year guidance—particularly the narrow $5.23–$5.37 non-GAAP EPS range—signals no material deviation from expectations despite macro uncertainties cited in forward-looking risk disclosures. Share repurchase activity ($125M in Q1) and $655M remaining authorization further demonstrate capital discipline aligned with shareholder return priorities. CEO Fred Lowery’s commentary emphasizes technology-enabled growth, operational agility, and market share gains as key levers—not just cost takeouts—suggesting sustainable momentum beyond near-term efficiency gains.